Literature DB >> 9811676

Cytokine response in multiple lymphoid tissues during the primary phase of feline immunodeficiency virus infection.

G A Dean1, N C Pedersen.   

Abstract

Type 1 and 2 cytokine mRNA responses were measured at various time periods and in various lymphoid compartments during the acute stage (first 4 months) of feline immunodeficiency virus (FIV) infection in laboratory cats. Cytokine responses were correlated with virus replication. Virus was detected in plasma and tissue from day 14 postinfection (p.i.) onward, peaked at 56 to 70 days, and declined greatly by 70 days. Virus replication was highest in the thymus, followed by spleen, mesenteric lymph nodes, and cervical lymph nodes. Baseline cytokine levels were highest in the mesenteric lymph nodes and lowest in the cervical lymph nodes. Cytokine upregulation after FIV infection was most dramatic in the cervical lymph nodes, with the greatest increase in interleukin-10 (IL-10) and gamma interferon (IFN-gamma). Cytokine transcription in the mesenteric lymph node increased above baseline by day 14 p.i. for IFN-gamma, IL-12p40, IL-4, and IL-10, while elevations in the spleen were mainly for IFN-gamma, IL-12p40 and IL-10. An increase in IFN-gamma, IL-10, and IL-12p40 occurred in the thymus at day 56 p.i., concomitant with the onset of thymitis. In general, type 2 cytokines (IL-4 and IL-10) were increased greater than 1 log over baseline, while the elevations in type 1 cytokines were less than 1 log. In the tissues tested, CD4(+) cells were the primary source of IL-2, IL-4, and IL-10. Both CD4(+) and CD8(+) cells produced IFN-gamma, while no cytokine mRNA was detected in B cells. These results demonstrate the presence of a heterogeneous cytokine response in lymphoid tissues during the primary stage of FIV infection. The nature and intensity of the response differed from one compartment to the other and, in the case of the thymus, also with inflammatory changes. Although limited in scope, the present study confirms the usefulness of the FIV infection model in studying early cytokine events that lead to the secondary subclinical carrier state typical of most lentivirus infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9811676      PMCID: PMC110431     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Comparative interleukin (IL-2)/interferon IFN-gamma and IL-4/IL-10 responses during acute infection of macaques inoculated with attenuated nef-truncated or pathogenic SICmac251 virus.

Authors:  O Benveniste; B Vaslin; R Le Grand; A Cheret; F Matheux; F Theodoro; M P Cranage; D Dormont
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

2.  Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node.

Authors:  G A Dean; G H Reubel; P F Moore; N C Pedersen
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

3.  Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.

Authors:  T Harrer; E Harrer; S A Kalams; T Elbeik; S I Staprans; M B Feinberg; Y Cao; D D Ho; T Yilma; A M Caliendo; R P Johnson; S P Buchbinder; B D Walker
Journal:  AIDS Res Hum Retroviruses       Date:  1996-05-01       Impact factor: 2.205

4.  Cytokine pattern in relation to disease progression in human immunodeficiency virus-infected children.

Authors:  S Than; R Hu; N Oyaizu; J Romano; X Wang; S Sheikh; S Pahwa
Journal:  J Infect Dis       Date:  1997-01       Impact factor: 5.226

5.  Early cytokine and chemokine gene expression in lymph nodes of macaques infected with simian immunodeficiency virus is predictive of disease outcome and vaccine efficacy.

Authors:  W Zou; A A Lackner; M Simon; I Durand-Gasselin; P Galanaud; R C Desrosiers; D Emilie
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

6.  HIV-specific cellular and humoral immune responses in primary HIV infection.

Authors:  E Connick; D G Marr; X Q Zhang; S J Clark; M S Saag; R T Schooley; T J Curiel
Journal:  AIDS Res Hum Retroviruses       Date:  1996-08-10       Impact factor: 2.205

7.  Kinetics of appearance of neutralizing antibodies in 12 patients with primary or recent HIV-1 infection and relationship with plasma and cellular viral loads.

Authors:  I Pellegrin; E Legrand; D Neau; P Bonot; B Masquelier; J L Pellegrin; J M Ragnaud; N Bernard; H J Fleury
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-04-15

8.  Kinetics of cytokine expression during primary human immunodeficiency virus type 1 infection.

Authors:  C Graziosi; K R Gantt; M Vaccarezza; J F Demarest; M Daucher; M S Saag; G M Shaw; T C Quinn; O J Cohen; C C Welbon; G Pantaleo; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

9.  Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS.

Authors:  Y Rivière; M B McChesney; F Porrot; F Tanneau-Salvadori; P Sansonetti; O Lopez; G Pialoux; V Feuillie; M Mollereau; S Chamaret
Journal:  AIDS Res Hum Retroviruses       Date:  1995-08       Impact factor: 2.205

10.  The route of antigen entry determines the requirement for L-selectin during immune responses.

Authors:  M D Catalina; M C Carroll; H Arizpe; A Takashima; P Estess; M H Siegelman
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

View more
  20 in total

1.  In vivo depletion of CD4(+)CD25(hi) regulatory T cells is associated with improved antiviral responses in cats chronically infected with feline immunodeficiency virus.

Authors:  S Rochelle Mikkelsen; Stacie K Reckling; Erin A Egan; Gregg A Dean
Journal:  Virology       Date:  2010-05-14       Impact factor: 3.616

2.  Development and validation of a multiplex microsphere-based assay for detection of domestic cat (Felis catus) cytokines.

Authors:  Britta A Wood; Kevin P O'Halloran; Sue Vandewoude
Journal:  Clin Vaccine Immunol       Date:  2011-01-05

Review 3.  Going wild: lessons from naturally occurring T-lymphotropic lentiviruses.

Authors:  Sue VandeWoude; Cristian Apetrei
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Thymic lesions in cats infected with a pathogenic molecular clone or an ORF-A/2-deficient molecular clone of feline immunodeficiency virus.

Authors:  R M Norway; P C Crawford; C M Johnson; A Mergia
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus.

Authors:  K A Hayes; A J Phipps; S Francke; L E Mathes
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  In vivo depletion of CD4+CD25+ regulatory T cells in cats.

Authors:  S Rochelle Smithberg; Jonathan E Fogle; Angela M Mexas; Stacie K Reckling; Susan M Lankford; Mary B Tompkins; Gregg A Dean
Journal:  J Immunol Methods       Date:  2007-10-22       Impact factor: 2.303

7.  Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus.

Authors:  Rosemary Stevens; Kristina E Howard; Sushila Nordone; MaryJo Burkhard; Gregg A Dean
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 8.  Lentivirus-induced immune dysregulation.

Authors:  Mary B Tompkins; Wayne A Tompkins
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

9.  EIAV S2 enhances pro-inflammatory cytokine and chemokine response in infected macrophages.

Authors:  Lina Covaleda; Frederick J Fuller; Susan L Payne
Journal:  Virology       Date:  2009-11-28       Impact factor: 3.616

10.  Mucosal challenge with cell-associated or cell-free feline immunodeficiency virus induces rapid and distinctly different patterns of phenotypic change in the mucosal and systemic immune systems.

Authors:  Kristina E Howard; Mary Jo Burkhard
Journal:  Immunology       Date:  2007-07-16       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.